|Bid||3.50 x 900|
|Ask||5.12 x 800|
|Day's Range||3.98 - 4.17|
|52 Week Range||3.96 - 5.94|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.40|
Chimerix (CMRX) delivered earnings and revenue surprises of 11.36% and 27.32%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Durham, North Carolina-based company said it had a loss of 39 cents. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
DURHAM, N.C., Aug. 08, 2018-- Chimerix, a biopharmaceutical company developing novel antivirals to address unmet medical needs, today reported financial results and provided a corporate update for the ...
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Chimerix, Inc. (NASDAQ: CMRX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 8:30 AM Eastern Time. To ...
DURHAM, N.C., Aug. 01, 2018-- Chimerix, a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that it will host a live conference call and audio webcast ...
On July 23, ContraVir Pharmaceuticals stock closed at $0.95, which represents ~12% growth from its 52-week low of $0.85 on July 20 and 4.7% growth from its close of $0.91 on July 20. ContraVir Pharmaceuticals hit its 52-week high of $6.60 on October 17, 2017. On July 23, ContraVir Pharmaceuticals stock started rising after the company gave an update on its phase 1/2A trial of CRV431.
NEW YORK, June 29, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Webster ...
Chimerix (CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced results from preclinical studies supporting further evaluation of CMX521, the first direct-acting antiviral specifically for the treatment and prevention of norovirus. CMX521 showed activity in vitro against all strains of norovirus tested, suggesting broad efficacy against human noroviruses and supporting the ongoing Phase 1 study. The data will be presented in an oral and poster presentation at the 31st International Conference on Antiviral Research (ICAR) hosted by the International Society for Antiviral Research (ISAR) in Porto, Portugal.
The ASCO conference closed Tuesday, although presentations at the conference triggered some huge stocks moves . Nektar Therapeutics (NASDAQ: NKTR ) slumped about 42 percent, while Deciphera Pharmaceuticals ...
Durham-based biopharma Chimerix has banked a new designation from the U.S. Food and Drug Administration.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Five Below Inc (NASDAQ: FIVE ) stock was trading higher ...
Chimerix (CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for brincidofovir for the treatment of smallpox. Chimerix has been working with the Biomedical Advanced Research and Development Authority (BARDA) since 2011 to develop brincidofovir as a medical countermeasure for smallpox, demonstrating improved survival rates following confirmed orthopoxvirus infections in multiple animal models.
Chimerix (CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, announced that President and Chief Executive Officer M. Michelle Berrey, MD, MPH will deliver remarks before the House Committee on Energy and Commerce Subcommittee on Health at the hearing titled “Examining the Reauthorization of the Pandemic and All-Hazards Preparedness Act” at 10 a.m. ET on Wednesday, June 6 in Washington, D.C. The purpose of the hearing is to reauthorize certain programs under the Pandemic and All-Hazards Preparedness Act (PAHPA), which originally passed in 2006 and seeks to improve the United States’ public health and medical preparedness and response capabilities for emergencies, whether deliberate, accidental or natural. The draft reauthorization legislation would increase funding for the Biomedical Advanced Research and Development Authority (BARDA) and the Project BioShield Special Reserve Fund, a secure funding source for the purchase and stockpile of critical medical countermeasures such as vaccines, therapeutics and diagnostics.
Examining how Chimerix Inc (NASDAQ:CMRX) is performing as a company requires looking at more than just a years’ earnings. Below, I will run you through a simple sense check toRead More...
The Durham, North Carolina-based company said it had a loss of 42 cents per share. The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research ...
NEW YORK, NY / ACCESSWIRE / May 7, 2018 / Chimerix, Inc. (NASDAQ: CMRX ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 7, 2018 at 8:30 AM Eastern Time. To listen ...
Amid pushing its antiviral drug forward, Durham-based Chimerix (Nasdaq:CMRX) has made a number of new additions to its board of directors and named a female board chair.
For Durham-based Chimerix, fighting a virus known to cause the common cold is not a task it takes lightly.